Humana Inc.

ticker: HUM step: 01 generated: 2026-05-12 source: quick-research

Humana Inc. (HUM) — Business Overview

Business Description

Humana is the second-largest Medicare Advantage (MA) insurer in the United States and one of the most senior-focused health-services companies in the S&P 500. The company operates two reporting segments — Insurance (predominantly Medicare Advantage + state Medicaid + military) and CenterWell (a vertically integrated senior-focused care services platform combining primary care, pharmacy, and home health). 83% of Humana's premiums and services revenue come from contracts with the federal government, the highest government concentration of any major US insurer.

Revenue Model

• Insurance segment (~92% of revenue): Premiums collected from CMS (Centers for Medicare & Medicaid Services) for Medicare Advantage and Medicare Part D enrollment, state Medicaid contracts, and TRICARE (military). MA accounts for ~14% of revenue from individual MA contracts directly.
• CenterWell segment (~8% of external revenue, ~28% including intersegment): Three sub-businesses: (1) CenterWell Pharmacy (mail-order PBM for Humana members and external), (2) CenterWell Primary Care (employed senior-focused primary care clinics — 100,600+ patients added in 2025, +25%; serves Medicaid in 13 states), (3) CenterWell Home Solutions (home health services and hospice).

The vertically integrated model is the key strategic distinction: CenterWell captures the medical-loss-ratio (MLR) dollar that would otherwise go to third-party providers, lowering effective cost of care for senior members while creating an alternative growth engine independent of Insurance margin volatility.

Products & Services

Insurance:

• Individual Medicare Advantage HMO, PPO, Special Needs Plans (SNPs)
• Group Medicare Advantage (employer / retiree)
• Medicare Part D standalone prescription drug plans
• Medicaid managed care (state contracts in 22+ states)
• TRICARE (military) — east region administrator
• Stand-alone dental, vision, life products
• Group commercial health insurance (sub-scale, has been deemphasized)

CenterWell Healthcare Services:

• CenterWell Primary Care (employed senior-focused PCP clinics)
• CenterWell Pharmacy (mail-order + specialty pharmacy)
• CenterWell Home Health (acquired Kindred at Home)
• CenterWell Hospice
• CenterWell Senior Primary Care (Medicaid expansion)

Customer Base & Go-to-Market

• Medicare Advantage members (~5.7M): Senior citizens 65+ (plus dual-eligibles and SNPs); Humana is the #2 MA carrier behind UnitedHealthcare
• Medicare Part D members: Stand-alone prescription drug plan participants
• Medicaid members: State-contracted managed care across 22+ states
• TRICARE: Military families in the East region (federal contract)
• CenterWell patients: ~500K+ across primary care, home health, pharmacy
• Federal customer: CMS is effectively Humana's largest "customer" — 83% of premiums and services revenue derives from federal contracts

Sales channels: AEP (Annual Enrollment Period) marketing, broker / agent networks, direct-to-consumer, plus group contract sales for employer-retiree plans.

Competitive Position

Humana is the second-largest Medicare Advantage insurer with ~5.7M individual MA members (vs. UnitedHealth's ~10M+). The company's competitive moat is narrower and more senior-focused than UnitedHealth's broader UnitedHealthcare + Optum vertical integration. Key competitive advantages: (1) MA scale + senior-focused brand — strongest brand recognition among Medicare-age consumers, (2) CenterWell vertically integrated care — owns the primary care, pharmacy, and home health channels that drive MA medical-cost-trend management, (3) AEP marketing engine — historically the most effective marketing organization for Medicare enrollment, (4) National county footprint — operates in 85% of US counties (down from 89%) with material scale advantages. Key challenges: 2025 STAR ratings collapse (only 25% of members in 4-star+ plans, down from 94% in 2024) — a structural revenue headwind hitting 2026 P&L; modest 2026 STAR recovery (14% in 4.5-star+); higher-than-expected MA medical cost trend (utilization persistent in 2024–2025); $1.5–2B+ annual STAR-related revenue impact; UNH vertical integration advantages widening the competitive gap. The MA recovery thesis is the principal driver of HUM's investment narrative.

Key Facts

• Founded: 1961
• Headquarters: Louisville, KY
• Employees: ~67,000
• Exchange: NYSE
• Sector / Industry: Health Care / Health Care Plans
• Market Cap: ~$30B (May 2026)
• 2025 individual MA membership: ~5.7M
• 2026 individual MA membership growth target: ~25% YoY
• Operates in 85% of US counties (2026)
• 83% of premiums and services revenue from federal government contracts

ticker: HUM step: 12 generated: 2026-05-12 source: quick-research

Humana Inc. (HUM) — Investment Catalysts & Risks

Bull Case Drivers

1. Cyclical earnings recovery from depressed base — 2025 normalized EPS was ~$17, 2026 compresses to ~$9 under STAR Ratings headwind. Consensus models recovery to ~$15 in 2027 and ~$26 in 2028 as: (1) STAR ratings improve for bonus year 2027, (2) medical cost trend normalizes, (3) CMS 5% effective rate increase reduces depth of benefit cuts. The valuation already prices a worst-case outcome — even partial recovery supports material re-rating, potentially $260–300+ vs current trading.

2. MA membership growth ~25% in 2026 — Despite STAR headwinds, Humana's customer-led benefit strategy and improved retention are driving ~25% individual MA membership growth in 2026. This volume base sets up earnings power for 2027/2028 when STAR ratings recover and the membership flows through at improved margins.

3. CenterWell vertically integrated care platform — CenterWell Primary Care added 100,600 patients in 2025 (+25%), now serves Medicaid in 13 states. The vertically integrated model owns primary care + pharmacy + home health channels that drive medical cost trend management. Long-term, CenterWell could approach UNH-Optum-like margin-resilience by capturing the MLR dollar internally.

4. STAR ratings litigation optionality + 2027 STAR recovery — Humana has appealed to the 5th Circuit Court. Even partial favorable ruling could meaningfully reduce the STAR headwind. Separately, the 2026 STAR cycle showed modest improvement (14% in 4.5+ star plans vs. 3% in 2025), suggesting the corrective actions are working — a clean 2027 STAR cycle would unlock material bonus revenue.

Bear Case Risks

1. 2026 STAR Ratings headwind is real and large — Analyst estimates of $1–3B 2026 revenue impact from STAR bonus payment cliff. Approximately 30% of 2026 MA membership growth is concentrated in 3.5-star contracts, delaying STAR recovery. The Q4 2024 $541M loss demonstrated how fast margin compression can occur when STAR + medical cost combine.

2. Medical cost trend persistence — MA medical cost trend has outpaced program funding for two years running. If utilization continues at elevated levels through 2026, MLR could rise above the 92.75% guide, deepening MA segment losses below breakeven and compressing free cash flow needed to fund the membership ramp.

3. Competitive disadvantage vs. UnitedHealth's vertical integration — UnitedHealthcare + Optum generates a combined $615B+ revenue base with margin resilience Humana cannot match in the medium term. UNH has 78% of MA members in 4+ star plans (vs. Humana's 25%). The widening competitive gap creates structural disadvantage on benefit design, network, and STAR ratings management.

4. Litigation risk + regulatory exposure — Humana has lost two consecutive STAR ratings challenges (district court + circuit). 5th Circuit appeal is final domestic step. If lost, no near-term path to recovering bonus revenue except through 2027 STAR cycle improvement. Additionally, Medicare Advantage faces ongoing CMS scrutiny on coding intensity (V28 RADV), prior authorization, and supplemental benefits — all potential overhangs.

Upcoming Events

• Q2 2026 earnings: Late July 2026 — focus on AEP 2027 marketing strategy, membership trajectory, medical cost trend
• CMS Advance Notice 2027 (early 2026): Rate framework for next bonus year
• STAR Ratings 2027: Released October 2026 — most important annual catalyst
• Q3 2026 earnings: Late October 2026 — includes STAR Ratings 2027 impact
• 5th Circuit STAR Ratings appellate decision: Pending
• CMS final 2027 rate notice: April 2026

Analyst Sentiment

Sell-side consensus is mixed — split between cyclical-recovery bulls and STAR/margin-trend bears. Average 12-month price targets cluster around $260–$300 (vs. current trading near $260). TIKR / bull-case analysts model ~250% potential upside if MA recovery delivers; bear-case analysts see continued multiple compression with EPS staying suppressed. The principal divergence is on the timing of STAR Ratings recovery + medical cost normalization — a "delayed-by-12-months" recovery scenario meaningfully changes the path.

Research Date

Generated: 2026-05-12